<DOC>
	<DOC>NCT02712554</DOC>
	<brief_summary>The purpose of this study is to assess the abuse potential of CL-108 tablets, including the abuse deterrent effects of promethazine, following oral administration, relative to hydrocodone/acetaminophen (APAP) tablets and placebo in non-dependent, recreational opioid users.</brief_summary>
	<brief_title>A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route</brief_title>
	<detailed_description>The purpose of this study is to assess the abuse potential of CL-108 tablets, including the abuse deterrent effects of promethazine, following oral administration, relative to hydrocodone/acetaminophen (APAP) tablets and placebo in non-dependent, recreational opioid users; to assess the cognitive and behavioral effects of CL-108 tablets following oral administration relative to hydrocodone/APAP tablets and placebo in non-dependent, recreational opioid users; and to assess the safety of orally administered CL-108 tablets relative to hydrocodone/APAP tablets and placebo in non-dependent, recreational opioid users.</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Hydrocodone</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<criteria>BMI within 18.0 to 33.0 kg/m2, inclusive (minimum weight of 50.0 kg at Screening) Healthy, as determined by no clinically significant medical history, physical examination findings, 12lead ECG findings, vital signs measurements, and laboratory results at screening, as judged by the investigator Current opioid users who had used oral opioids for recreational (nontherapeutic) purposes, at least 10 times in the past year Drug or alcohol dependence within the last 12 months (except nicotine) Subjects who had ever been in treatment for substance use disorders (except smoking cessation History of presence of any clinically significant cardiac, neurologic, pulmonary, psychiatric, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, dermatologic, renal, or other major disease at screening, which in the opinion of the investigator, would have jeopardized the safety of the subject or the validity of the study results History or presence of hypotension, judged to be clinically significant based on investigator judgement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Pain</keyword>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
</DOC>